Back to top
more

Ecolab (ECL)

(Delayed Data from NYSE)

$253.55 USD

253.55
990,657

-1.78 (-0.70%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $253.42 -0.13 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 14% (215 out of 251)

Industry: Chemical - Specialty

Better trading starts here.

Zacks News

Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion amid JNJ entering into a definitive agreement to acquire the company.

GE HealthCare (GEHC) Unveils Head-Only MR Scanner SIGNA MAGNUS

GE HealthCare's (GEHC) new SIGNA MAGNUS can delve deep into the brain's microstructure, microvasculature and function, providing researchers with a clearer picture of neurological diseases and disorders.

Should You Invest in the First Trust Water ETF (FIW)?

Sector ETF report for FIW

Avanos (AVNS) Q1 Earnings & Revenues Surpass Estimates

Avanos' (AVNS) first-quarter results show strong bottom-line improvement along with decent growth in segmental revenues.

Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up

Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.

GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment

GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.

Here's Why Ecolab (ECL) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

DENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/Y

DENTSPLY SIRONA's (XRAY) first-quarter 2024 results showcase a decline in year-over-year sales with an improved bottom line.

Cardinal Health (CAH) Beats on Q3 Earnings, Ups '24 EPS View

Cardinal Health's (CAH) third-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.

Baxter (BAX) Q1 Earnings Beat Estimates, '24 EPS View Raised

Baxter (BAX) reports better-than-expected first-quarter earnings and sales. BAX's quarterly results reflect solid demand for a range of its medically essential products.

Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y

Glaukos' (GKOS) first-quarter 2024 results showcase growth in revenues while earnings miss the Zacks consensus Estimate. Loss at the operating level raises concern as well.

Inari Medical (NARI) Q1 Earnings Miss Estimates, OpEx Rises

Inari Medical's (NARI) first-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the companies continue to incur operating losses.

Here's Why Ecolab (ECL) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

These 2 Basic Materials Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Here's Why You Should Hold Lantheus (LNTH) in Your Portfolio Now

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

GE HealthCare (GEHC) Q1 Earnings In Line, Sales Volume Decline

GE HealthCare's (GEHC) first-quarter results witness declining segmental revenues in imaging, ultrasound and patient care. The bottom line improves on better pricing.

Ecolab (ECL) Q1 Earnings Surpass Estimates, Margins Rise

Ecolab's (ECL) robust performance across the majority of its segments drives its first-quarter sales despite business challenges.

Ecolab (ECL) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Ecolab (ECL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ecolab (ECL) Surpasses Q1 Earnings and Revenue Estimates

Ecolab (ECL) delivered earnings and revenue surprises of 0.75% and 0.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Revvity (RVTY) Q1 Earnings and Revenues Surpass Estimates

Revvity's (RVTY) first-quarter results showcase a decline in life sciences segmental revenues. However, the company's earnings and revenues beat their respective estimates.

U.S. Silica (SLCA) Q1 Earnings and Revenues Lag Estimates

U. S. Silica's (SLCA) earnings and sales miss estimates in the first quarter amid lower sales volumes in Oil & Gas.

Bruker's (BRKR) Balanced Segmental Growth, Innovation Aid

Bruker (BRKR) revenues continue to be driven by the strength of end markets, including academic, government and industrial.

Is Ecolab (ECL) Stock Outpacing Its Basic Materials Peers This Year?

Here is how Ecolab (ECL) and Pan American Silver (PAAS) have performed compared to their sector so far this year.

Indrajit Bandyopadhyay headshot

What's in Store for These 5 Medical Device Stocks in Q1 Earnings?

Here is a sneak peek into how the five medical device stocks, SYK, GEHC, ECL, NARI and MMSI, might fare in their quarterly results slated to be released tomorrow.

Philips (PHG) Receives FDA Warning Letter Regarding CT Systems

Philips (PHG) receives a warning letter from the FDA in respect of a manufacturing plant in China regarding faults in the manufacturing of CT systems.